B+L, Nicox glaucoma candidate meets primary endpoint in phase III studies
September 30th 2014Valeant Pharmaceuticals International’s wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. have announced positive top-line results from the pivotal phase III studies conducted with latanoprostene bunod (Vesneo, previously known as BOL-303259-X and NCX 116) for the reduction of IOP in patients with glaucoma or ocular hypertension.
Using femtosecond laser in pediatric Marfan’s syndrome with ectopia lentis
September 23rd 2014A femtosecond laser can create circular, well-centered capsulotomies to facilitate implantation of capsular tension rings and IOLs without decentration in pediatric patients with Marfan’s syndrome. Tim Schultz, MD, and H. Burkhard Dick, MD, of the University Eye Clinic Bochum, Bochum, Germany, described the case of a 10-year-old boy with Marfan’s syndrome.
8 reasons why AMA calling for design overhaul of EHRs
September 23rd 2014The American Medical Association (AMA)-in responding to physicians’ demands for solutions to electronic health record (EHR) systems that have neglected usability as a necessary feature-has outlined eight priorities for improving EHR usability that would benefit caregivers and patients.
Valeant, Croma agreement to expand B + L surgical line
September 23rd 2014The recent agreement between Valeant and Croma-which would provide for the distribution of Croma’s ophthalmology products in Western Europe-is expected to expand Bausch + Lomb’s (B + L) ophthalmic portfolio in the United States.
Nicox acquires rights to anti-viral drop; buys French ophthalmic firm
September 23rd 2014Nicox S.A has agreed to acquire the Carragelose anti-viral eye drop program from Marinomed Biotechnologie GmbH of Austria. The acquisition will provide Nicox with an anti-viral ophthalmic product, expected to launch in Europe within 2 years and pending CE marking.
Editor’s Blog: IOLs again grab the attention at ESCRS
September 16th 2014The European Society of Cataract and Refractive Surgeons (ESCRS) never fails to entice ophthalmology with cutting-edge technology, and the XXXII Congress in London has not disappointed attendees. This year’s congress has displayed a wide range of new technologies from cataract and refractive platforms to diagnostic units to surgical instruments. From all the equipment presented, IOL advances have again captured the attention of attendees.
Recalling adventures from days as a military physician in France
September 15th 2014In retrospect-even though Army life was not for me-going to France was a unique opportunity for a young man to gain perspective on the culture of Western Europe. With my 2-year “vacation” at an end, I was ready to focus on my future in ophthalmology.
IVAN data mined for insights on intravitreal anti-VEGF systemic safety
September 15th 2014Analyses of data from the Inhibition of VEGF in Age-related Choroidal Neovascularisation trial conducted to explore relationships between temporal changes in serum VEGF and safety events showed that at 1 year, a larger fall from baseline serum VEGF was associated with a lower hazard of death.
Lifestyle cooperative poised for growth as U.S. population ages
September 15th 2014The self-pay, lifestyle health care market is poised for huge growth as the population of the United States ages. A new cooperative offers a host of tools and services to help board-certified ophthalmologists capitalize on opportunities in the self-pay market.
DARPin delivers promising results in phase II study of exudative AMD:
September 15th 2014Abicipar pegol was at least as effective as ranibizumab for treatment of exudative age-related macular degeneration, and appeared to have a longer duration of action In a randomized, double-masked phase II study.